UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 45-0834299 ( State or other jurisdi ...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Jennifer Good – President and Chief Executive Officer Lisa Delfini – Chief Financial Officer Conference Call Participants Serge Belanger – Needham & Company Sean Kim – Jones Trading Annabel Samimy – Stifel Operator Good afternoon and welcome to the Trevi Therapeutics’ Q1 2023 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded. Various remarks that manag ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 45-0834299 ( State or other jurisd ...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Jennifer Good - President & Chief Executive Officer Lisa Delfini - Chief Financial Officer David Clark - Chief Medical Officer Conference Call Participants Leland Gershell - Oppenheimer Nat Charoensook - SVB Securities Sean Kim - Jones Trading Mayank Mamtani - B. Riley Securities Operator Good afternoon and welcome to the Trevi Therapeutics Q4 and Year-End 2022 Earnings Conference Call. [Op ...

Financial Performance - The company reported an accumulated deficit of $210.1 million as of December 31, 2022, primarily due to research and development and general and administrative expenses [509]. - The company has not generated any revenue from product sales and has incurred net losses each year since its inception [509]. - Net loss for the year ended December 31, 2022, was $29.2 million, compared to a net loss of $33.9 million in 2021, reflecting an improvement of $4.8 million [533]. - Interest income increased by $1.7 million to $1.7 million in 2022, primarily due to higher cash equivalents and marketable securities balances [536]. - Other income, net for 2022 was $0.7 million, compared to other expense, net of $1.5 million in 2021, mainly due to the absence of a $0.4 million expense recorded in 2021 related to shares issued to Lincoln Park [536]. - Total operating expenses for 2022 were $29.9 million, a decrease of $2.6 million from $32.5 million in 2021 [533]. Research and Development - The Phase 2 CANAL trial for Haduvio demonstrated statistically significant results for daytime cough frequency reduction (p<0.0001) with 38 subjects enrolled [503]. - A Phase 2 clinical trial for Haduvio targeting refractory chronic cough is expected to commence in the third quarter of 2023 [505]. - The Phase 2b/3 PRISM trial for prurigo nodularis showed statistically significant results on all primary and secondary endpoints [506]. - The company expects to conduct an additional Phase 3 clinical trial to support NDA submissions for Haduvio for prurigo nodularis [507]. - The company anticipates an increase in research and development expenses as it pursues regulatory approval and prepares for a potential commercial launch of Haduvio [524]. - Research and development expenses decreased by $3.2 million, or 13.7%, to $19.8 million in 2022 from $23.0 million in 2021, primarily due to reduced clinical trial costs [534]. Funding and Cash Flow - As of December 31, 2022, the company had cash, cash equivalents, and marketable securities totaling $120.5 million [516]. - The company may need substantial additional funding to support ongoing operations and growth strategy [518]. - The company expects to incur substantial expenditures for clinical development and regulatory approval of Haduvio, impacting future funding needs [552][553]. - The company has no committed external funding sources and will need to secure additional financing through various means [558]. - The company believes existing cash and marketable securities will fund operations into 2026, excluding costs for additional clinical trials [556]. - Net cash used in operating activities was $28.2 million, a decrease from $28.9 million in 2021 [546][547]. - Net cash used in investing activities for 2022 was $107.4 million, primarily for marketable securities [549]. - Net cash provided by financing activities in 2022 was $111.3 million, significantly up from $20.8 million in 2021 [550][551]. Debt and Obligations - The SVB Term Loan requires interest-only payments until March 2022, with full repayment due by February 1, 2024 [532]. - The SVB Term Loan was originally $14.0 million with an interest rate of either the prime rate plus 1.00% or 4.25% [542]. - The SVB Loan Agreement includes restrictive covenants that may limit the company's operational flexibility [559]. - Failure to raise sufficient capital could lead to delays or abandonment of product development programs [559]. Accounting and Financial Reporting - Financial statements prepared in accordance with U.S. GAAP, requiring estimates and assumptions affecting reported amounts of assets and liabilities [560]. - Research and development expenses are expensed as incurred, with nonrefundable advance payments deferred and capitalized [562]. - Stock-based compensation expense recognized using fair value-based method, influenced by stock price and various complex variables [564]. - Fair value estimates of financial instruments made at a specific point in time, with cash and cash equivalents considered representative of fair value [576]. - No new accounting pronouncements adopted during the year ended December 31, 2022, materially impacting consolidated financial statements [580]. - Company has elected not to avail itself of the JOBS Act exemption, subjecting it to the same new or revised accounting standards as other public companies [579]. - Research and development accruals estimated based on service levels performed and study progress, included in accrued expenses [563]. - Fair value measurements categorized into three levels, with Level 1 being quoted prices in active markets and Level 3 involving unobservable inputs [578]. - Company assesses uncertain tax positions based on sustainability and measures at the largest amount of benefit greater than fifty percent likely to be realized [573]. - Stock options' expected term estimated using the "simplified method," averaging the vesting term and original contractual term [567].

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Jennifer Good - President and CEO Lisa Delfini - CFO Conference Call Participants Annabel Samimy - Stifel Serge Belanger - Needham & Company Operator Good afternoon, and welcome to the Trevi Therapeutics Q3 2022 Earnings Conference Call. [Operator Instructions] Please note, today's event is being recorded. Various remarks that management makes during this conference call about the compan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 45-0834299 ( State or other jurisdiction of incorporation or organization) 195 Church Street, 14th Floor New Haven, Connecticut 06510 (Address of principal ex ...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Jennifer Good – President and Chief Executive Officer Lisa Delfini – Chief Financial Officer Bill Forbes – Chief Development Officer Conference Call Participants Annabel Samimy – Stifel Serge Belanger – Needham & Company Leland Gershell – Oppenheimer Nathan Weinstein – Aegis Operator Good afternoon, and welcome to the Trevi Therapeutics Second Quarter 2022 Earnings Conference Call. [Operat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38886 TREVI THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 45-0834299 ( State or other jurisdi ...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Jennifer Good – President and Chief Executive Officer Lisa Delfini – Chief Financial Officer Bill Forbes – Chief Development Officer Conference Call Participants Serge Belanger – Needham & Company Annabel Samimy – Stifel Nathan Weinstein – Aegis Capital Operator Good afternoon, and welcome to the Trevi Therapeutics First Quarter 2022 Earnings Conference Call. [Operator Instructions] Please no ...